Pharmaceutical companies Pfizer and Valneva have announced the start of a phase III clinical trial, "

"

Vaccine makers hope data from phase 3 study confirms positive results from previous phases.

It is planned to involve about 6,000 participants aged 5 years and older in the study. It will be held in 50 cities located in regions where Lyme disease is highly endemic, including Finland, Germany, the Netherlands, Poland, Sweden and the United States..

The vaccine is given in three doses over several months, followed by a booster dose 12 months later..

[see_also ids\u003d"

Upon successful completion of the third phase of the study, Pfizer may apply for a biologics license with the US Food and Drug Administration and a marketing authorization application with the European Medicines Agency in 2025.

According to the U.S. Centers for Disease Control and Prevention, Lyme disease is the most common tick-borne disease.. A tick must be on a person for at least 36 hours to transmit the bacteria to them.. If Lyme disease is not diagnosed and treated promptly, it can affect the joints, heart, and nervous system..

Vietnam develops African swine fever vaccine.